28.07.2015 • News • Dede Willams • PTA • DuPont

Jiaxing Petrochemical Licenses Invista PTA Process

Jiaxing Petrochemical, part of China’s Tongkun Group, has licensed Invista's P8 process technology for its second purified terephthalic acid (PTA) production line in Zhejiang Province, China.

The investment is designed to strengthen Tongkun's upstream and downstream business as well as increasing its risk resistance capacity, production scale and competitiveness.

Jiaxing Petrochemical's first PTA line, which came on stream in 2012, also licenses the process owned by Invista Performance Technologies (IPT). The former DuPont business licenses a number of technologies for production of a wide range of compounds in polyester, polyurethane and nylon value chains.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Top-Feature

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.